> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Dr. Reddy’s Xeglyze
- URL: https://www.fdaweb.com/regulatory-review-period-for-dr-reddys-xeglyze/
- Published: 2022-07-13T12:00:00.000Z
- Updated: 2026-09-14T17:51:48.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152261

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Dr. Reddy’s Xeglyze (abametapir), indicated for the topical treatment of head lice infestation in patients six months of age and older. The regulatory review period is 4,573 days, of which 2,797 days occurred during the testing phase and 1,776 days during the approval phase. To view the notice, click [here](https://public-inspection.federalregister.gov/2022-14430.pdf?ref=fdaweb.com).